Mode
Home
Research
Clinical Trials Drug Pipeline Weekly Digests
Reference
Conditions Medications
Community
Questions
Text Size
Log in / Sign up
Home › Conditions › Binge Eating Disorder

Binge Eating Disorder

2 published articles · Updated continuously

Clinical Trial Landscape

Clinical Trials for Binge Eating Disorder

28 trials tracked for Binge Eating Disorder: 14 in phase 3 or 4 and 4 with published results. The most-cited published study has 157 citations.

28Trials tracked
14Phase 3 & 4
0Recruiting
4With published results
Phase distribution
Phase 3 14 Phase 2 4 Other / NA 10
  1. Phase 3 Evaluate the Maintenance of Efficacy of SPD489 in Adults Aged 18-55 Years With Moderate to Severe Binge Eating Disorder Completed · 157 cited
  2. Phase 3 Behavioral and Pharmacologic Treatment of Binge Eating and Obesity: Acute Treatment Completed · 87 cited
  3. Phase 3 Cognitive-Behavioral and Pharmacologic (LDX) Treatment of Binge-Eating Disorder and Obesity: Acute Treatment Completed · 1 cited
  4. Phase 3 A Study to Evaluate a Drug (Dasotraline) on the Safety, Effectiveness and How Well the Body Tolerates it, in Adults With Moderate to Severe Binge Eating Disorder Completed
  5. Phase 3 Dasotraline Binge Eating Disorder Extension Study Completed
  6. Phase 3 Behavioral and Pharmacologic Treatment of Binge Eating and Obesity: Maintenance Therapy Completed
Show 22 more trials
  1. Phase 3 Behavioral and Pharmacologic Treatment of Binge Eating and Obesity: Specialist Treatment Completed
  2. Phase 3 Efficacy and Mechanisms of Naltrexone+Bupropion for Binge Eating Disorder Completed
  3. Phase 3 Cognitive-Behavioral and Pharmacologic (LDX) Treatment of Binge-Eating Disorder and Obesity: Medication Change for Non-Responders Completed
  4. Phase 3 Cognitive-Behavioral and Pharmacologic (LDX) Treatment of Binge-Eating Disorder and Obesity: Maintenance Treatment Completed
  5. Phase 3 SPD489 in Adults Aged 18-55 Years With Moderate to Severe Binge Eating Disorder Completed
  6. Phase 3 Craving, Binge Eating and Obesity Completed
  7. Phase 3 SPD489 in Adults Aged 18-55 Years With Moderate to Severe Binge Eating Disorder Completed
  8. Phase 3 Open Label Extension in Adults With Binge Eating Disorder (BED) Completed
  9. Phase 2 Forced-dose Titration of SPD489 in Adults With Binge Eating Disorder Completed
  10. Phase 2 A Trial of Centanafadine Efficacy, Safety, and Tolerability in Adult Subjects With Binge Eating Disorder Completed
  11. Phase 2 Vortioxetine for Binge Eating Disorder Completed
  12. Phase 2 Multicenter Study to Evaluate the Efficacy and Safety of Oral ACT-539313 in the Treatment of Adults With Moderate to Severe Binge Eating Disorder Completed
  13. N/A Acceptance-based Group Intervention for Binge Eating Completed
  14. N/A Uniting Couples in the Treatment of Binge-Eating Disorder Completed
  15. N/A Binge Eating Disorder Treatment Study Completed
  16. N/A Weight Loss Treatment for Veterans With Binge Eating Completed
  17. N/A Evaluation of the Communities of Healing Mentorship/Support Group Program: Assessment of Preliminary Efficacy Completed
  18. N/A Improving Weight Loss Outcomes for Binge Eating Disorder. Completed
  19. N/A Reward Re-Training: A New Treatment to Address Reward Imbalance During the COVID-19 Pandemic Completed
  20. N/A Follow-Up Extension to the Family Study of Binge Eating Disorder Completed
  21. N/A Neural Response to Food Stimuli: fMRI Changes Following Cognitive Behavioral Therapy for Binge Eating Disorder Completed
  22. N/A Treatment of Binge Eating Disorder in Obesity: Naltrexone/ Bupropion Combination Versus Placebo Completed

Showing the 28 most-cited and recently-updated of 28 trials. Browse the full registry →

Trial data sourced from ClinicalTrials.gov. Counts describe the research landscape and are not a treatment recommendation. Informational only — not medical advice.

HCP Mode — summaries include clinical detail, trial data, and statistical outcomes.
Patient Mode — summaries use plain language, avoiding clinical jargon.
FDA Approves Vyvanse (lisdexamfetamine) for Binge Eating Disorder in Adults
Psychiatry FDA Approval
FDA Approves Vyvanse (lisdexamfetamine) for Binge Eating Disorder in Adults FDA approves Vyvanse to treat binge eating disorder in adults
The FDA approved Vyvanse (lisdexamfetamine) for moderate to severe binge eating disorder (BED) in adults.
The FDA has approved Vyvanse (lisdexamfetamine) for moderate to severe binge eating disorder in adults.
FDA Apr 29, 2026
FDA Approves Vyvanse (lisdexamfetamine) for Binge Eating Disorder
Psychiatry FDA Approval
FDA Approves Vyvanse (lisdexamfetamine) for Binge Eating Disorder FDA approves Vyvanse to treat binge eating disorder in adults
FDA approved Vyvanse (lisdexamfetamine) for moderate to severe binge eating disorder (BED) in adults.
The FDA approved Vyvanse for moderate to severe binge eating disorder in adults. It is a stimulant already used for ADHD. This gives patient…
FDA Apr 29, 2026